Identification of Generic Drugs in the FDA Adverse Event Reporting System

被引：0
|
作者：
Iyer, Geetha S. [1 ,2 ]
Marimuthu, Sathiya Priya [1 ,3 ]
Segal, Jodi B. [1 ,2 ,4 ]
Singh, Sonal [1 ,4 ]
机构：
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Drug Safety & Effectiveness, Baltimore, MD USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[3] Johns Hopkins Sch Med, Dept Med, Div Clin Pharmacol, Baltimore, MD USA
[4] Johns Hopkins Sch Med, Div Gen Internal Med, Dept Med, Baltimore, MD USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2016年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
696
引用
收藏
页码：406 / 407
页数：2
相关论文
共 50 条
  • [31] Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
    Wen, Ming-Tao
    Li, Jia-Cheng
    Lu, Bo-Wen
    Shao, Hua-Rong
    Ling, Pei-Xue
    Liu, Fei
    Li, Gang
    Luo, Di
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [32] REPORTING FREQUENCY OF QT-INTERVAL ABNORMALITIES IN THE FDA ADVERSE EVENT REPORTING SYSTEM (FDA_AERS)
    Raschi, E.
    Poluzzi, E.
    Koci, A.
    De Ponti, F.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 84 - 84
  • [33] Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system
    Xiao, Yao
    Chen, Yiqian
    Huang, Yan
    Xiao, Yuan
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01)
  • [34] Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system
    Yao Xiao
    Yiqian Chen
    Yan Huang
    Yuan Xiao
    [J]. Scientific Reports, 13
  • [35] Adverse Event Reporting for Compounded Drugs
    不详
    [J]. BIOPHARM INTERNATIONAL, 2019, 32 (10) : 10 - 10
  • [36] Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system
    Fukuda, Akiho
    Tahara, Kohei
    Hane, Yuuki
    Matsui, Toshinobu
    Sasaoka, Sayaka
    Hatahira, Haruna
    Motooka, Yumi
    Hasegawa, Shiori
    Naganuma, Misa
    Abe, Junko
    Nakao, Satoshi
    Takeuchi, Hirofumi
    Nakamura, Mitsuhiro
    [J]. PLOS ONE, 2017, 12 (09):
  • [37] Sparse Batch Number Reporting for Biologicals in FDA's Adverse Event Reporting System (AERS)
    Vermeer, N. S.
    Straus, S. M.
    Teeuwisse, A. K. Mantel
    Egberts, T. C.
    Leufkens, H. G.
    De Bruin, M. L.
    [J]. DRUG SAFETY, 2011, 34 (10) : 1002 - 1002
  • [38] Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
    Li, Dongxuan
    Gou, Jinghui
    Zhu, Jun
    Zhang, Tongyan
    Liu, Feng
    Zhang, Daojun
    Dai, Liyang
    Li, Wenjun
    Liu, Qinglong
    Qin, Chunmeng
    Du, Qian
    Liu, Songqing
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [39] Differences in Anaphylaxis Reporting Among Cephalosporins: Analysis of the FDA Adverse Event Reporting System Database
    Shah, Divya
    Stone, Cosby
    Rukasin, Christine
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB77 - AB77
  • [40] Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
    Li, Ying
    Yepes, Antonio Jimeno
    Xiao, Cao
    [J]. DRUG SAFETY, 2020, 43 (09) : 893 - 903
12345